METHODS: From inception to May 4, 2022, manual searches were conducted to identify all eligible literature using the PubMed database for the published phase III clinical trial and a randomize-controlled trial testing the role of adjuvant chemoradiotherapy in operable gastric cancer.
RESULTS: Two trials with a total of 1004 patients were selected as a result. Adjuvant CRT was found to have no effect on disease-free survival (DFS) in gastric cancer patients treated with D2 surgery (HR: 0.70 (0.62-1.02), p: 0.07). However, patients with intestinal-type gastric cancers exhibited significantly longer DFS (HR: 0.58 (0.37-0.92), p = 0.02).
CONCLUSIONS: After D2 dissection, adjuvant CRT improved DFS in patients with intestinal-type gastric cancers but not in those with diffuse-type gastric cancers.
方法:从开始到2022年5月4日,使用PubMed数据库进行手动搜索,以识别所有符合条件的文献,用于已发布的III期临床试验和随机对照试验,测试辅助放化疗在可手术胃癌中的作用。
结果:两项试验共选择1004名患者作为结果。发现辅助CRT对D2手术治疗的胃癌患者的无病生存期(DFS)没有影响(HR:0.70(0.62-1.02),p:0.07)。然而,肠型胃癌患者表现出明显更长的DFS(HR:0.58(0.37-0.92),p=0.02)。
结论:D2解剖后,辅助CRT可改善肠型胃癌患者的DFS,但不适用于弥漫型胃癌患者。